

Trust specifics

Deposit information

The Dow Jones Total Market Portfolio, Enhanced Index Strategy 2024-2

Objective

The Portfolio seeks above-average capital appreciation. The Portfolio invests in stocks of domestic companies selected by applying separate uniquely specialized enhanced sector strategies." The Portfolio strategy combines ten enhanced sector strategies: the Basic Materials Strategy, the Consumer Goods Strategy, the Consumer Services Strategy, the Energy Strategy, the Financials Strategy, the Health Care Strategy, the Industrials Strategy, the Technology Strategy, the Telecommunications Strategy and the Utilities Strategy. Each strategy makes up that percentage of the initial portfolio as its respective sector makes up of the Dow Jones U.S. Index.

Performance of a hypothetical \$10,000 investment

From 12/31/93 - 02/29/24

11011112/01	175 02/2														
\$500,000	Portfo \$414	olio stra 1,917	ategy												
400,000		Jones l 1,042	J.S. Ind	lex											
300,000		500 Inc 1,404	lex												
200,000														A	
100,000	Initial in \$10,000		nt									A REAL PROPERTY.			
0															
12/9	93 '95	'97	'99	'01	'03	'05	'07	'09	'11	'13	'15	'17	'19	'21	02/24

	12/93	'95	'97	'99	'01	'0.	3 '05
Annua total r				rtfolio rategy	DJ U In	J.S. dex	S&P 500 Index
1994			-1	L.65%	0.2	1%	1.32%
1995			34	1.72	36.6	2	37.58
1996			24	1.82	22.0	2	22.96
1997			36	5.07	31.8	1	33.36
1998			18	3.58	24.9	0	28.58
1999			64	1.94	22.7	2	21.04
2000			21	L.60	-9.2		-9.10
2001			21	L.80	-11.9	5	-11.89
2002			-6	5.12	-22.0	8	-22.10
2003			52	2.55	30.7	5	28.68
2004			19	9.06	12.0	1	10.88
2005			14	1.07	6.3	3	4.91
2006).44	15.6		15.79
2007			-2	2.97	6.1		5.49
2008			-46	5.84	-37.1	5	-37.00
2009			54	1.41	28.8	2	26.47
2010			20).85	16.7	2	15.06
2011				3.45	1.3	-	2.11
2012			10).21	16.5		16.00
2013			41	L.20	32.9	6	32.38
2014			11	L.05	12.9	4	13.68
2015			-2	1.39	0.6	2	1.37
2016			17	7.40	12.2	4	11.95
2017			17	7.87	21.4	8	21.82
2018			-14	1.72	-4.9		-4.39
2019			25	5.87	31.1	4	31.48
2020			5	5.26	20.3	9	18.39
2021				3.49	26.4		28.68
2022				9.27	-19.4	-	-18.13
2023			21	l.93	26.5	0	26.26
Thru C)2/29/24	1	1	l.56	6.9	0	7.11

Average annual

total return (for the period ended on 12/31/23)	Portfolio Strategy	DJ U.S. Index	S&P 500 Index
1-Year	21.93%	26.50%	26.26%
3-Year	6.72	8.83	9.98
5-Year	10.00	15.27	15.67
10-Year	7.27	11.60	12.02
15-Year	12.25	13.94	13.96
20-Year	7.66	9.81	9.69
25-Year	11.53	7.77	7.55
Inception (01/01/93)	13.16	10.09	10.14
1993 - 2023	Portfolio Strategy	DJ U.S. Index	S&P 500 Index
Standard deviation	22.94%	18.36%	18.29%
Sharpe ratio	0.48	0.43	0.43
Source: Bloomberg L.P.			

The graph represents a hypothetical \$10,000 investment in the trust strategy (not any actual trust) and the Dow Jones U.S. Index and the S&P 500 Index from 12/31/93 through 02/29/24. The graph assumes the sum of the initial investment (\$10,000) and all dividends (including those on stocks trading ex-dividend as of the last day of the year) and appreciation during a year are reinvested at the end of that year.

All strategy performance is hypothetical (not any actual trust) and reflects trust sales charges at the beginning of each calendar year of 1.85% and expenses but not brokerage commissions on stocks or taxes. Past performance is no guarantee of future results. Actual returns will vary from hypothetical strategy returns due to timing differences, expenses and because the trust may not be invested equally in all stocks or be fully invested at all times. In any given year the strategy may lose money or underperform the index. Returns are calculated by taking year-end prices, subtracting them from the prices at the end of the following year (adjusting for any stock splits that might have occurred during the year) and adding dividends received for the period divided by starting price. Average annual total return and total return measure change in the value of an investment plus dividends, assuming quarterly reinvestment of dividends. Average annual total return reflects annualized change while total return reflects aggregate change and is not annualized.

Standard deviation is a measure of volatility that represents the degree to which an investment's performance has varied from its average performance over a particular period. Standard deviation does not compare the volatility of an investment relative to other investments or the overall stock market. The more an investment's return varies from the investment's average return, the more volatile the investment. Standard deviation is based on past performance and is no guarantee of future results.

The Sharpe ratio is a risk-adjusted measure calculated using standard deviation on excess return to determine reward per unit of risk. The higher the Sharpe ratio, the better the historical risk-adjusted performance.

Please keep in mind that high, double-digit and/or triple-digit returns are highly unusual and cannot be sustained. Investors should also be aware that these returns were primarily achieved during favorable market conditions.

See page 4 for the footnotes on trust specifics.

Not a Deposit Not FDIC Insured Not Guaranteed by the Bank May Lose Value Not Insured by any Federal Government Agency

Public offering price per unit ¹	\$10.00
Minimum investment (\$250 for IRA	As) ² \$1,000.00
Deposit date	03/08/24
Termination date	06/12/25
Distribution dates	25th day of July,
	October and January
Record dates	10th day of July,
	October and January
Term of trust	15 months
Symbol	ITMBDC
Historical 12 month distributions ⁺	\$0.0821
ESTM242 Sales charge and C	USIPs
Brokerage	
Sales charge ³	
Deferred sales charge	1.35%
Creation and development fee	0.50%
Total sales charge	1.85%
Last deferred sales charge paymen	t date 12/10/24
CUSIPs	
Cash	46146C-72-1
Reinvest	46146C-73-9
Historical 12 month distribution rat	te† 0.82%
Fee-based	
Sales charge ³	
Fee-based sales charge	0.50%
CUSIPs	
Fee-based cash	46146C-74-7
Fee-based reinvest	46146C-75-4
Historical 12 month distribution	
rate ⁺ (fee-based)	0.83%

Investors in fee-based accounts will not be assessed the deferred sales charge for eligible fee-based purchases and must purchase units with a fee-based CUSIP.

The historical 12 month distributions per unit and each historical 12 month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's actual distributions or distribution rate. The historical 12 month distributions per unit amount is based upon the weighted average of the actual distributions paid by the securities included in the trust over the 12 months preceding the trust's deposit date, and is reduced to account for the effects of fees and expenses which will be incurred when investing in a trust. Each historical 12 month distribution rate is calculated by dividing the historical 12 month distributions amount by the trust's initial \$10 public offering price per unit. There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The distributions paid by the trust, as well as the corresponding rates, may be higher or lower than the figures shown due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, currency fluctuations, the sale of trust securities to pay any deferred sales charges, trust fees and expenses, variations in the trust's per unit price, or with the call, maturity or the sale of securities in the trust. Distributions made by certain securities in the trust

* An enhanced sector (or "index") strategy refers to a unit investment trust strategy, sponsored by Invesco Capital Markets, Inc., that seeks to outperform an index by investing in an objectively selected subset of stocks from the same index.


Portfolio composition (As of the business day before deposit date)

Portfolio composition (As of the busines	ss day before
Basic Materials	
Alcoa Corporation	AA
Ashland, Inc.	ASH
Celanese Corporation	CE CF
CF Industries Holdings, Inc. Chemours Company	CF CC
Cleveland-Cliffs, Inc.	CLF
Commercial Metals Company	CMC
Dow, Inc.	DOW
DuPont de Nemours, Inc.	DD
Eastman Chemical Company	EMN
FMC Corporation	FMC
Huntsman Corporation	HUN
International Flavors & Fragrances, Inc.	IFF
LyondellBasell Industries, N.V.	LYB
Mosaic Company Newmont Corporation	MOS NEM
Nucor Corporation	NUE
Olin Corporation	OLN
Royal Gold, Inc.	RGLD
Scotts Miracle-Gro Company - CL A	SMG
Consumer Goods	
Autoliv, Inc.	ALV
Bunge Global S.A.	BG
Clorox Company	CLX
Coty, Inc CL A	COTY
Deckers Outdoor Corporation	DECK
e.l.f. Beauty, Inc.	ELF
General Motors Company	GM
Gentex Corporation	GNTX
Ingredion, Inc. Lamb Weston Holdings, Inc.	INGR LW
Lear Corporation	LEA
Levi Strauss & Company - CL A	LEVI
Lululemon Athletica, Inc.	LULU
Mondelez International, Inc., CL A	MDLZ
PVH Corporation	PVH
Ralph Lauren Corporation - CL A	RL
Skechers U.S.A., Inc CL A	SKX
Tapestry, Inc.	TPR
Toll Brothers, Inc.	TOL
Whirlpool Corporation	WHR
Consumer Services	41471
Amazon.com, Inc.	AMZN
American Airlines Group, Inc. Aramark	AAL
Burlington Stores, Inc.	BURL
Cable One, Inc.	CABO
Cardinal Health, Inc.	CAH
CarMax, Inc.	KMX
Charter Communications, Inc CL A	CHTR
Delta Air Lines, Inc.	DAL
Expedia Group, Inc.	EXPE
Live Nation Entertainment, Inc.	LYV
Murphy USA, Inc.	MUSA
News Corporation - CL A Performance Food Group Company	NWSA PFGC
Pinterest, Inc CL A	PINS
Southwest Airlines Company	LUV
Target Corporation	TGT
Uber Technologies, Inc.	UBER
US Foods Holding Corporation	USFD
Walt Disney Company	DIS
Energy	
APA Corporation	APA
Baker Hughes Company - CL A	BKR
Cheniere Energy, Inc.	LNG
Chesapeake Energy Corporation	CHK
Chord Energy Corporation	CHRD

deposit date)	
Devon Energy Corporation	DVN
EOG Resources, Inc.	EOG
Exxon Mobil Corporation	XOM
Halliburton Company HF Sinclair Corporation	HAL DINO
Marathon Oil Corporation	MRO
Marathon Petroleum Corporation	MPC
Murphy Oil Corporation	MUR
New Fortress Energy, Inc.	NFE
NOV, Inc.	NOV
Ovintiv, Inc.	OVV
Range Resources Corporation	RRC
Schlumberger N.V. Targa Resources Corporation	SLB TRGP
Valero Energy Corporation	VLO
Financials	120
American International Group, Inc.	AIG
Assurant, Inc.	AIZ
Axis Capital Holdings, Ltd.	AXS
Bank OZK	OZK
Brighthouse Financial, Inc.	BHF
Capital One Financial Corporation	COF
Citigroup, Inc.	С
CNA Financial Corporation	CNA
Comerica, Inc.	CMA
Corebridge Financial, Inc.	CRBG EWBC
East West Bancorp, Inc. Fifth Third Bancorp	FITB
Hartford Financial Services Group, Inc.	HIG
Lincoln National Corporation	LNC
MetLife, Inc.	MET
OneMain Holdings, Inc.	OMF
Unum Group	UNM
Voya Financial, Inc.	VOYA
Webster Financial Corporation	WBS
Western Alliance Bancorporation	WBS WAL
Western Alliance Bancorporation Health Care	WAL
Western Alliance Bancorporation Health Care AbbVie, Inc.	WAL
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc	WAL ABBV ALKS
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc.	WAL ABBV ALKS AMGN
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company	WAL ABBV ALKS AMGN BMY
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc.	WAL ABBV ALKS AMGN
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation	WAL ABBV ALKS AMGN BMY CNC
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation	WAL ABBV ALKS AMGN BMY CNC CVS
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC
Western Alliance BancorporationHealth CareAbbVie, Inc.Alkermes plcAmgen, Inc.Bristol-Myers Squibb CompanyCentene CorporationCVS Health CorporationDaVita, Inc.Gilead Sciences, Inc.Haemonetics CorporationHalozyme Therapeutics, Inc.Humana, Inc.Incyte CorporationJazz Pharmaceuticals plcMolina Healthcare, Inc.Perrigo Company plcPremier, Inc CL ATenet Healthcare CorporationUnited Therapeutics CorporationViatris, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Industrials	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halth Corporation Hadzyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Industrials Acuity Brands, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halth Corporation Hadzyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Industrials Acuity Brands, Inc. Advanced Drainage Systems, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Industrials Acuity Brands, Inc. Advanced Drainage Systems, Inc. Alight, Inc CL A	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Industrials Acuity Brands, Inc. Alight, Inc CL A	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH AYI WMS ALIT ALSN
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Industrials Acuity Brands, Inc. Advanced Drainage Systems, Inc. Alight, Inc CL A	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Advanced Drainage Systems, Inc. Alight, Inc CL A Ander Systems, Inc. Adity Brands, Inc. Alight, Inc CL A	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH AYI WMS ALIT ALSN AWI
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Advanced Drainage Systems, Inc. Alight, Inc CL A Haustrials Acuity Brands, Inc. Alight, Inc CL A Eindustrials Acuity Brands, Inc. Alight, Inc CL A Builders FirstSource, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH AYI WMS ALIT ALSN AWI BLDR
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Advanced Drainage Systems, Inc. Alight, Inc CL A Allison Transmission Holdings, Inc. Armstrong World Industries, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc. Coherent Corporation EMCOR Group, Inc.	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH AVI WMS ALIT ALSN AWI BLDR CSL COHR EME
Western Alliance Bancorporation Health Care AbbVie, Inc. Alkermes plc Amgen, Inc. Bristol-Myers Squibb Company Centene Corporation CVS Health Corporation DaVita, Inc. Gilead Sciences, Inc. Haemonetics Corporation Halozyme Therapeutics, Inc. Humana, Inc. Incyte Corporation Jazz Pharmaceuticals plc Molina Healthcare, Inc. Perrigo Company plc Premier, Inc CL A Tenet Healthcare Corporation Viatris, Inc. Zimmer Biomet Holdings, Inc. Advanced Drainage Systems, Inc. Alight, Inc CL A Ander Drainage Systems, Inc. Alight, Inc CL A Aulison Transmission Holdings, Inc. Armstrong World Industries, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc. Coherent Corporation	WAL ABBV ALKS AMGN BMY CNC CVS DVA GILD HAE HALO HUM INCY JAZZ MOH PRGO PINC THC UTHR VTRS ZBH AYI WMS ALIT ALSN AWI BLDR CSL COHR

NEXTracker, Inc CL A	NXT
Oshkosh Corporation	OSK
Owens Corning	OC
PACCAR, Inc.	PCAR
Parker-Hannifin Corporation	PH
Stericycle, Inc.	SRCL
Textron, Inc.	TXT
Vertiv Holdings Company - CL A	VRT
Vontier Corporation	VNT
Technology	
Akamai Technologies, Inc.	AKAM
Amdocs, Ltd.	DOX
Ciena Corporation	CIEN
Cirrus Logic, Inc.	CRUS
DXC Technology Company	DXC
EPAM Systems, Inc.	EPAM
Garmin, Ltd.	GRMN
Gen Digital, Inc.	GEN
Intel Corporation	INTC
Lumentum Holdings, Inc.	LITE
Meta Platforms, Inc CL A	META
MKS Instruments, Inc.	MKSI
Okta, Inc CL A	OKTA
Salesforce, Inc.	CRM
Skyworks Solutions, Inc. Snap, Inc CL A	SWKS SNAP
	SEDG
SolarEdge Technologies, Inc. TD SYNNEX Corporation	SNX
Twilio, Inc CL A	TWLO
Zoom Video Communications, Inc CL A	ZM
Telecommunications	2111
AT&T, Inc.	Т
Frontier Communications Parent, Inc.	FYBR
T-Mobile US, Inc.	TMUS
Verizon Communications, Inc.	VZ
Utilities	
AES Corporation	AES
Ameren Corporation	AEE
American Water Works Company, Inc.	AWK
Avangrid, Inc.	AGR
Avista Corporation	AVA
Black Hills Corporation	BKH
Clearway Energy, Inc CL A	CWEN.A
Clearway Energy, Inc CL C	CWEN
Dominion Energy, Inc.	D
Entergy Corporation	ETR
Evergy, Inc.	EVRG
National Fuel Gas Company	NFG
NextEra Energy, Inc.	NEE
NiSource Inc	NI
ONE Gas, Inc.	OGS
PG&E Corporation	PCG
Portland General Electric Company	POR
PPL Corporation	POR
UGI Corporation	UGI
Xcel Energy, Inc.	XEL

The trust portfolio is provided for informational purposes only and should not be deemed as a recommendation to buy or sell the individual securities shown above. Invesco's history of offering unit investment trusts began with the acquisition of the Sponsor by Invesco Ltd. in June 2010. Invesco unit investment trusts are distributed by the Sponsor, Invesco Capital Markets, Inc. and broker dealers including Invesco Distributors, Inc. Both firms are indirect, wholly owned subsidiaries of Invesco Ltd.



The Dow Jones Total Market Portfolio, Enhanced Index Strategy:

The Dow Jones Total Market Portfolio, Enhanced Index Strategy combines all of the enhanced sector strategies listed below into one comprehensive investment that spans all the sectors within the Dow Jones U.S. Index.

Basic Materials Strategy 20 stocks		Industrials Strategy	20 stocks
Consumer Goods Strategy 20		Technology Strategy	20 stocks
Consumer Services Strategy		Telecommunications Strategy	4 stocks
Energy Strategy	20 stocks	Utilities Strategy	20 stocks
Financials Strategy	20 stocks	The Dow Jones Total Market Portfolio,	
Health Care Strategy	20 stocks	Enhanced Index Strategy*	184 stocks

*Although each enhanced sector strategy is designed to produce a certain number of stocks, it is possible that a particular strategy could produce less. For example, certain series of this strategy have resulted in less than 10 stocks within the Telecommunications Strategy, as shown in the chart above. Beginning with the stocks in the Dow Jones U.S. Index, the strategies exclude the bottom 1% of stocks based on market capitalization. The strategies then rank each remaining company in the Dow Jones U.S. respective sector index from highest to lowest based on the following strategy screens for each: Basic materials strategy—Dividend yield, Price/book value ratio, Price/sree cash flow ratio, Price/sales ratio, Price/sales to live-year average, Operating margin. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Basic Materials Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Price/Book Value Ratio is ranked higher. This trust invests in the basic materials sector. Basic materials companies are subject to price and supply fluctuations, excess capacity, economic recession, domestic and international politics, government regulations, volatile interest rates, consumer spending trends and overall capital spending levels. Consumer goods strategy—Price/cash flow ratio, Operating income change last quarter, Total return for the past six months, One-year earning stocks by total score being 1 and the highest score being 1 und the highest score being 1 sectors. The strategies the score being 1 sectors in the Dow Jones U.S. Consumer Goods Index. The strategy her nanks the remaining stocks by total score and selects the top 20 stocks, provided th

With the higher score for Long-term Expected Profit Growth is ranked higher. *This trust invests in the consumer services sector.* Companies that provide consumer services face risks such as intense competition, the lack of serious barriers to entry for on-line entrants, economic recession and a slowdown in consumer spending trends. A portfolio concentrated in a single market sector may present more risk than a portfolio broadly diversified over several sectors. **Energy strategy**—Enterprise value to EBITDA, Price/sales ratio, Price/sales to three-year average, Five-year earnings growth, Long-term expected profit growth, Gross margin trend. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Oil & Gas Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Long-Term Expected Profit Growth is ranked higher. *This trust invests in the energy industry. There are certain risks specific to the energy sector, including the potential adverse effect of state and federal regulation and increasing costs of natural resources.*

Financials strategy—Price/earnings ratio, Price/book value ratio, Price/sales ratio, Earnings predictability, Long-term expected profit growth, Tangible book one-year change. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Financials Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Tangible Book One-Year Change is ranked higher. The trust invests in the financial services industry and may present more risk than a more diversified investment. There are certain risks specific to the financial services sector, including the potential adverse effects of economic recession, volatile interest rates, and state and federal regulations. Health care strategy—Enterprise value to EBITDA, Price/earnings ratio, Price/free cash flow ratio, One-year net income growth, Return on equity, Gross margin. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Health Care Index. The strategy then ranks the remaining stocks by total score and selects the ton 20 stocks. The stocks of any Invesco affiliate with the lowest score being 1 and the highest score being the total number of stocks in the Dow

Jones U.S. Health Care Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Return on Equity is ranked higher. This trust invests in the health care sector. There are certain risks specific to the health care companies such as governmental regulation and the risk that a product may never come to pass.

Industrials strategy—Price/earnings ratio, Price/free cash flow ratio, Long-term expected profit growth, EPS revisions current quarter, EPS surprise last quarter, Total return for the past six months. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Industrials Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Price/Earnings Ratio is ranked higher. This trust invests in the industrials sector. General risks of industrials companies include the general state of the economy, intense competition, consolidation, domestic and international politics, excess capacity and consumer spending trends.

Technology strategy—Price/book value ratio, Price/sales to five-year average, Price/sales ratio, Total return for the past six months, Net profit margin, Tangible book five-year change. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Technology Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Total Return for the Past Six Months is ranked higher. This trust invests in the technology industry. There are certain risks specific to information technology stocks such as volatile stock prices, rapid product obsolescence, and speculative trading.

Telecommunications strategy—Dividend yield, Enterprise value to EBITDA, Price/cash flow ratio, Three-year sales growth, Total return for the past six months, Asset turnover trend. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Telecommunications Index. The strategy then ranks the remaining stocks by total score and selects the top 10 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Enterprise Value to EBITDA is ranked higher. This trust invests in the telecommunications industry. There are certain risks specific to telecommunication stocks such as volatile stock prices, rapid product obsolescence, and speculative trading as well as government changes in regulations.

Utilities Strategy-Price/earnings ratio, Price/book value ratio versus three-year average, Price/sales to three-year average, Price/cash flow ratio, Long-term expected profit growth, EBIT margin. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Utilities lindex. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Price/ Earnings Ratio is ranked higher. This trust invests in the utility industry, it may be highly susceptible to any economic, political, or regulatory occurrences affecting this industry.

In addition, for all strategies listed above, a company will be excluded and its stock will be replaced with the stock with the next highest total score, if the company is an affiliate of the Sponsor, if there is any restriction on the Sponsor's ability to purchase a company's stock, or, if based on publicly available information as of the selection date, a proposed corporate action would result in it not being the surviving company following a business combination or in its security being delisted.

Asset turnover trend—The median asset turnover for the four most recent quarters divided by the median asset turnover of the 12 most recent quarters. Asset turnover is the sum of the four most recent quarters of sales divided by the average of the four most recent quarters of assets. Cash flow to net income—Sum of the four most recent quarters of cash flow divided by sum of the four most recent quarters of net income. Cash flow is defined as income before extraordinary items plus depreciation and amortization. Dividend yield-The indicated annual dividend divided by the current stock price. Dividend yield to five-year median-Current dividend yield divided by the median dividend yield over the past 60 months. Earnings predictability-A ratio that seeks to measure of the stability of year-to-year earnings growth over the past 20 quarters. Calculated by dividing the standard deviation of year-to-year changes in per-share earnings by the average year-to-year change in per-share earnings. EBIT margin—Earnings before interest and taxes (EBIT) divided by sales. Enterprise value to EBITDA—Enterprise value divided by earnings before interest, taxes, depreciation and amortization (EBITDA). Enterprise value equials stock market capitalization plus sum of debt and preferred stock minus cash and cash equivalents. EPS change last quarter-Year-to-year change in operating earnings per share (EPS). Operating earnings exclude the effect of all nonrecurring items, including cumulative effect of accounting changes, discontinued operations, extraordinary items, special items, and one-time income tax expenses/benefits. EPS revisions current quarter-The net percentage of positive profit-estimate revisions. First, the number of earnings estimates for the next fiscal quarter that have been decreased from the prior month are subtracted from the number that have been increased. Next, that result is divided by the total number of earnings estimates for the guarter. EPS surprise last guarter-The difference between last quarter's actual earnings per share and the average estimate, divided by the absolute value of the actual earnings per share. Five-year earnings growth-Current price/sales ratio divided by median price/sales ratio over the past 60 months. Gross margin-Net sales in most recent four guarters minus cost of goods sold in most recent four quarters, with this total then divided by net sales. Gross margin trend-The median gross margin over the past four quarters divided by the median gross margin over the past 12 quarters. Long-term expected profit growth—The simple average of analysts' estimates for five-year growth in earnings per share. Net profit margin—Net income divided by sales. One-year earnings growth—The difference between operating earnings per share in the most recent four quarters share. Net profit margin-Net income divided by sales. One-year earnings growth-The difference between operating earnings per share in the most recent four quarters and the year-earlier quarter. Operating margin-Operating income before depreciation divided by sales, calculated for most recent four quarters one year earlier, expressed as a percentage. Operating income change last quarter-The difference between operating income in the latest quarter and the year-earlier quarter. Operating margin-Operating income before depreciation divided by sales, calculated for most recent four quarters one year earlier, expressed as a percentage. Net earnings per share in the most recent four quarters and net earnings per share in the four quarters one year earlier, expressed as a percentage. Net earnings exclude discontinued operations and extraordinary items. Price/book value ratio-Stock price divided by ger-share cash flow over past four quarters. With cash flow defined as net income plus depreciation and amortization. Price/cash flow ratio-Stock price divided by per-share cash flow over past four quarters. Price/free cash flow ratio-Stock price divided by earnings per share from operations over past four quarters. Price/free cash flow ratio-Stock price divided by earnings ratio-Stock price divided by mersents the net change in cash from all items classified in the operating activities section on a statement of cash flows, minus capital spending and cash dividends. Price/sales ratio-Stock price divided by median price/sales ratio over the past 36 months. Price/sales to five-year average-Current price/sales ratio divided by median price/sales ratio over the past 36 months. Price/sales to five-year average-Current price/sales ratio divided by median price/sales ratio over the past 36 months. Price/sales to five-year average-Current price/sales ratio divided by median price/sales ratio over the past 36 months. Price/sales to five-year average-Current price/sales ratio divided by median price/sales ratio over the past 36 months share over the past five years. Tangible shareholders equity equals shareholders equity minus intangible assets, such as goodwill. Three-year sales growth–The difference between per share sales in the most recent four quarters and per-share sales in the four quarters three years earlier, expressed as a percentage. Total return for the past six months-The percentage return on a stock over most recent six months, reflecting dividends and change in stock price.

About risk

There is no assurance the trust will achieve its investment objective. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the trust will decline and that the value of trust units may therefore be less than what you paid for them. This trust is unmanaged and its portfolio is not intended to change during the trust's life except in limited circumstances. Accordingly, you can lose money investing in this trust. The trust should be considered as a part of a long-term investment strategy and you should consider your ability to pursue it by investing in successive trusts, if available. You will realize tax consequences associated with investing from one series to the next.

Common stocks do not assure dividend payments. Dividends are paid only when declared by an issuer's board of directors and the amount of any dividend may vary over time. There can be no guarantee or assurance that companies will declare dividends in the future or that if declared, they will remain at current levels or increase over time.

The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your Units. This may occur at any point in time, including during the initial offering period. You could experience dilution of your investment if the size of the Portfolio is increased as Units are sold. There is no assurance that your investment will

maintain its proportionate share in the Portfolio's profiles and losses. Stocks of smaller capitalization companies are often more volatile than those of larger companies as a result of several factors such as limited trading volumes,

The Portfolio is concentrated in securities issued by companies in the technology industry. The technology industry faces risks related to rapidly changing technology, rapid product obsolescence, cyclical market patterns, evolving industry standards and frequent new product introductions. Negative developments in this industry will affect the value of your investment more than would be the case for a more diversified investment. The Dow Jones U.S. Index measures the performance of the U.S. equity broad market. The index is comprised of all the companies in the Dow Jones Large-Cap

Index, Dow Jones U.S. Index measures the performance of the 0.5. equity broad marked, the index to the performance of the 0.5. equity broad marked, the index to the performance of the 0.5. equity broad marked, the index to the performance of the order of the order of the performance of the performance of the order of the performance of th Care Index, the Dow Jones Industrials Index, the Dow Jones Technology Index, the Dow Jones Telecommunications Index and the Dow Jones Utilities Index, is not sponsored, endorsed, sold or promoted by Dow Jones, CME, or their respective affiliates, and Dow Jones, CME and their respective affiliates make no representation regarding the advisability of investing in this product.

The Standard & Poor's 500 Index is an unmanaged index generally representative of the U.S. stock market.

Indices are statistical composites and their returns do not include payment of any sales charges or fees an investor would pay to purchase the securities they represent. Such costs would lower performance. It is not possible to invest directly in an index. The historical performance of the indices are shown for illustrative purposes only; it is not meant to forecast, imply or guarantee the future performance of any particular investment or the trust, which will vary. 1 Including sales charges. As of deposit date.

2 Represents the value of 100 units on the deposit date. The value of the minimum investment amount of 100 units may be greater or less than \$1,000.00 following the deposit date. 3 Assuming a public offering price of \$10 per unit. There is no initial sales charge if the public offering price per unit is \$10 or less. If the public offering price per unit exceeds \$10, an initial

sales charge is paid at the time of purchase. The per unit amount of the initial sales charge is 1.85% of the dollar amount that the public offering price per unit exceeds \$10.

Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the trust, investors should ask their financial professional(s) for a prospectus or download one at invesco.com/uit.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

The Dow Jones Total Market Portfolio, Enhanced Index Strategy 2024-2